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Abstract
The role of non-alcoholic fatty liver disease (NAFLD) as a potential independent 
cardiovascular disease (CVD) risk factor has recently gained considerable attention because 
CVD is the common cause of death in NAFLD patients. We aimed to estimate the effects of 
vitamin D supplementation alone or in combination with calcium on atherogenic indices, liver 
function tests, and grade of disease in patients with NAFLD. One-hundred twenty NAFLD 
patients were randomized in a double-blind, placebo-controlled clinical trial as follows: 
D (1000 IU vitamin D), CaD (500 mg as calcium carbonate plus 1000 IU vitamin D) or P 
(placebo), once daily with meals over 12 weeks. Adjusted for all the baseline measures, 
reduction in serum ALT, AST, LDL-C/HDL-C, TC/HDL-C, and non-HDL-C were significantly 
higher in the CaD compared with the P group (p < 0.001, p = 0.03, p < 0.001, p < 0.001, p 
< 0.001 and p < 0.001, respectively). Also, mean difference of serum ALT, LDL-C/HDL-C, 
TC/HDL-C, and TG/HDL-C were significantly higher in the CaD than D group (p < 0.001, p 
= 0.006, p < 0.001 and p = 0.03, respectively). Serum non-HDL-C was marginally decreased 
in the CaD compared with the D group (p = 0.06). With considering the BMI changes as 
covariate, reduction in the grade of fatty liver was significantly higher in the CaD and D groups 
than the P (p < 0.001). The present study suggests that supplemental calcium combined with 
vitamin D, but not vitamin D alone, may reduce serum atherogenic indices, liver function tests, 
and grade of disease in patients with NAFLD.
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Introduction
Non- alcoholic fatty liver disease (NAFLD) is 
considered as liver manifestations of metabolic 
syndrome (MetS), which is an atherogenic 
condition (1). Most patients are overweight 
and/or obese, as well as have dyslipidemia, 
insulin resistance (IR), hypertension, and high 
waist circumference (WC) (2). Prevalence of 
atherosclerosis in NAFLD patients is high and 
this condition is independent on obesity and other 
established risk factors (3). The role of NAFLD 
as a potential independent cardiovascular disease 
(CVD) risk factor has recently gained considerable 
attention because CVD is the common cause of 
death in NAFLD patients (4). Dyslipidemia, 
as a common risk factor of NAFLD and CVD, 
up-regulates the transcription factor sterol 
regulatory element binding protein-1c (SREBP-
1c). Insulin and SREBP-1c synergistically 
stimulate genes involved in de-novo synthesis 
of lipids. Furthermore, SREBP-1c inhibits 
oxidation of free fatty acids and leads to increase 
in hepatic lipid content (5, 6). To compensate for 
the increased hepatic triglycerides (TG), the liver 
forms an atherogenic lipid profile, consisting 
of high TG levels, low high-density lipoprotein 
(HDL) cholesterol, increased small and dense 
low-density lipoprotein (LDL) particles, 
increased very low-density lipoprotein (VLDL) 
cholesterol levels, and elevated apolipoprotein 
B100 concentration; all of which are strongly 
associated with adverse cardiovascular outcomes 
(7-9). Non-high-density lipoprotein cholesterol 
(non-HDL-C) which reflects the cholesterol 
in all lipoprotein particles has become 
increasingly recognized as an important measure 
of atherogenesis (10). Among the CVD risk 
factors, vitamin D deficiency is the new one (11). 
Vitamin D deficiency is a pandemic problem and 
studies suggested that this might contribute to 
the worldwide increased prevalence of CVD (12, 
13). Several mechanisms have been proposed to 
account for this inverse relationship including 
anti-inflammatory effects, immune response 
modulation, fibrotic pathways, and cytokine’s 
secretion (14, 15). One study showed that calcium 
carbonate supplementation lead to a positive 
change in lipid profile and atherogenic indices 
in centrally obese patients (16). Roles of calcium 
and vitamin D are inter-twinning. To our the best 
knowledge, there is no study to assess the effects 
of calcium plus vitamin D on atherogenic indices 
in NAFLD patients compared with vitamin D, 
alone. The purpose of this study was to compare 
the effects of vitamin D supplementation with 
and without calcium for 12-wk on atherogenic 
indices in NAFLD patients controlled by dietary 
intake and physical activity levels. 
Experimental
A double-blind, placebo-controlled clinical 
trial was designed that aimed to the effects of 
vitamin D supplementation with and without 
calcium on weight loss, body fat, liver function 
enzymes, and atherogenic indices in NAFLD 
patients which were controlled by dietary 
intake and physical activity levels. Totally, 120 
NAFLD patients were selected from who were 
attending the Rasool-Akram Hospital, Tehran, 
Iran. Patients aged 18-65 y, BMI of 25-35 kg/
m2, serum 25 (OH) D level< 15 ng/mL and 
willingness to control sun exposure time, dietary 
and physical activity levels were included. The 
patients taking any supplement, drug for blood 
glucose and/or lipid control during at least the 
last 3 month, having pregnancy or given birth 
in the past year or planning a pregnancy in the 
next 6 month, having lactation, weight loss of 
≥10% of body weight within the six month 
before enrollment in the study, participation in 
a competitive sport, abnormal thyroid hormone 
concentration, intake of medications that could 
affect body weight and/or energy expenditure, 
allergy, smoking, diagnosis of chronic diseases 
including inflammatory diseases, heart, liver and 
renal failure, cancer, acute myocardial infarction, 
diabetes, stroke, or serious injuries and any other 
conditions that were not suitable for the trial as 
evaluated by the physician were excluded. The 
study was approved by the Ethical Committee 
of Iran University of Medical Sciences, Tehran, 
Iran. All subjects provided their signed consent 
before the study enrollment. At the screening 
visits, new diagnosed NAFLD patients proven by 
ultra-sonography underwent an examination by 
an Internist. After measuring baseline variables, 
eligible participants were randomly assigned by 
using a computer-generated random-numbers 
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method by the project coordinator. The patients 
were randomly assigned to one of the three 
groups: D group (n = 37) received one tablet 
containing 1000 IU of vitamin D (25µg/d as 
Calciferol; Jalinus Arya Co, Iran), CaD group (n 
= 37) received one tablet containing 500 mg/d 
as calcium carbonate plus 1000 IU vitamin D 
as calciferol (Jalinus Arya Co, Iran), placebo 
(P) group (n = 36) received placebo (25 µg/d as 
lactose; Jalinus Arya Co. Iran) after lunch with 
a glass of water for 12 weeks. Shape, color, and 
packaging of the placebo were exactly similar 
to the supplements. The dietary program was 
designed to introduce a 500-kcal energy deficit 
based on estimated energy requirements at the 
start of the study by an expert dietitian. Daily 
30 min moderate walking advised to all the 
participants. Dietary intake and physical activity 
level were assessed by a 3-d dietary food recall 
questionnaire and International Physical Activity 
questionnaire (IPAQ) that were completed three 
times during the study period (baseline and 
at the end of the 6th weeks and 12 th weeks of 
intervention). These dietary intake data were 
analyzed by the N4 software (Nutritionist 
4, First Data Bank, San Bruno, CA, USA). 
Compliance with the supplement consumption 
instructions was monitored once a week by 
telephone interviews. Researchers advised to 
the participants to control the direct sun-light 
exposure to less than 1 hour/day. Duration of 
sun-light exposure was monitored once a week 
in each telephone interview. 
Measurements
Anthropometric and biochemical 
measurements of all subjects were taken at the 
baseline and after 12 wk. Blood samples of 
the subjects were taken from the antecubital 
vein after 10-12 h fasting. After centrifugation 
for 20 min (3000 g), the serum samples were 
frozen simultaneously and stored at -80 °C until 
analyzed. In order to eliminate the probable 
effects of sex hormones on blood lipids, blood 
sampling was not performed between days 1 
and 5 of the menstrual cycle in women. At the 
baseline and after 12 weeks of treatment, the 
liver fat accumulation and serum lipid profile 
were measured for the groups. Lipid profile and 
liver enzymes were measured by an enzymatic 
method (Pars Azmoon Co. kit, Tehran, Iran) 
using Liasys autoanalyzer. 25-OH vitamin D 
was measured by ELISA kit (SE120139, Sigma 
Aldrich). 
Body weight was taken to the nearest 0.1 kg 
by using a calibrated Seca scale to the nearest 
100 gram with light clothing and no shoes. Body 
height was measured to the nearest 0.5 cm by using 
a wall-mounted stadiometer (Seca) in a barefoot 
and freestanding position. WC was measured 
with a rigid measuring tape and recorded to the 
nearest 0.5 cm. WC was measured at the halfway 
between the lower rib and the iliac crest (17). 
Body fat was measured by BIA (Bioelectrical 
Impedance Analyzer) setting at the beginning 
and end of the study. BIA (model BIA-109 RJL/
Akern Systems, Detroit, Michigan, USA) was 
connected to surface electrodes on the right hand 
and foot. BMI (Body Mass Index) was calculated 
according to the formula: BMI = weight/ height2 
(kg/m2). The demographic data were collected 
during the initial anthropometric assessment. 
Grades of fatty liver classification
Liver ultrasound device Siemens brand 
Sonoline G50 series and 3.5 to 5 MHz probe made 
of Germany was used for liver sonography. Liver 
steatosis was classified through sonographic 
echogenisity of liver as: 1) normal: echogenicity 
as the same as renal cortex 2) grade I: mild 
steatosis; increased hepatic echogenicity with 
visible periportal and diaphragmatic echogenicity 
3) grade II: moderate steatosis; increased hepatic 
echogenicity with imperceptible periportal 
echogenicity, without obscuration of diaphragm 
3) grade III: sever steatosis; increased hepatic 
echogenicity with imperceptible periportal 
echogenicity and obscuration of diaphragm (19). 
Sample size and statistical Analysis
In design of the study, we considered a power 
of 80% with a two-sided test with α =0.05 (type 
I error) and standard deviation (SD) difference 
of 3.5 for WC and 2 for BMI. On the basis of 
SDs, reported in similar studies (19), the number 
of subjects needed to be treated in order to 
detect this difference was 36/group. Given an 
anticipated dropout rate of 10 percent, we set the 
enrollment target at 40 subjects. 
All data were expressed by means ± SE. 
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The level of significance was set at P <0.05. 
Statistical analyses were performed with IBM 
SPSS Statistics software (version 18; IBM 
Corp). Normal distribution of the variables was 
checked by Kolmogorov Smirnov Test. One-way 
ANOVA followed by post-hoc test was used to 
test whether the differences between the mean 
values of the items studied in the groups were 
significant. The comparison of mean values of 
variables before and after the intervention in each 
group was examined by paired t-tests. ANCOVA 
test was used to compare mean difference of 
outcomes, adjusted for the baseline measures as 
covariate. Chi-square test was used to compare 
the qualitative variables before and at the end of 
the study. 
Results
Mean age of participants was not significantly 
different among groups (P group = 4410.8 ±  yr; 
D group=39.811 ±  yr; CaD group=38.3 ± 10.1 
yr, p > 0.05). There wasn’t significant difference 
in the sex of participants. 64.7% in the P, 59.5% 
in the D and 62.3% of participants in the CaD 
group were male. Time of sun-light exposure 
(hr/day) was not significantly different among 
the groups (p > 0.05). There was no significant 
difference in energy and nutrient intake at the 
beginning of the study among groups and also 
no significant change was seen at the end of the 
study (Table 1). The level of physical activity 
was not different among groups at the baseline, 
as well as at the end of the study. At baseline, 
there were no statistically significant differences 
in physical characteristics and biochemical 
measurements among the intervention groups 
(Table 2). BMI reduction in each group was 
shown after 12 wk of the study (P group= -1.4 
± 0.29 kg/m2, D group= -1.1 ± 0.13 kg/m2, 
CaD group= -1.3 ± 1.17 kg/m2, p < 0.001), but 
differences among the groups was not significant 
after 12 wk of the study, adjusted to the baseline 
measures (p =0.65). Reductions in body fat mass 
was significant in each group after 12 wk of the 
study (P group= -2.36 ± 0.49%, D group= -2.25 
± 0.36%, CaD group= -3.67 ± 0.46%, p <0.001). 
Adjusting to the baseline measures, there was 
significant difference in WHR among the groups 
after 12 wk of the study (p < 0.001). Adjusting 
to the baseline measures, serum ALT and AST 
levels were significantly different among the 
groups after 12 wk of the study (p < 0.001 
and p =0.04, respectively). Reduction in serum 
ALT level was significantly higher in the CaD 
(-14.4 ± 1.7 µmol/L) compared with the P (0.5 
± 2.06 µmol/L, p < 0.001), and the D (-3.5 ± 1.8 
µmol/L, p <0.001) group at the end of the study. 
Reduction in serum AST level was significantly 
higher in the CaD than the P group (-5.5 ± 0.6 
µmol/L vs. -2.5 ± 1.02 µmol/L, p = 0.03).  
In the CaD supplemented group, serum 
LDL-C/HDL-C, TC/HDL-C, TG/HDL-C and 
non-HDL-C levels were significantly decreased 
after 12-wk of supplementation (p < 0.001, p < 
0.001, p <0.001 and p = 0.001, respectively). In 
the D supplemented group, serum TG/HDL-C 
was significantly decreased at the end of the 
study (p <0.001). Atherogenic indices didn’t 
change in the P group (p > 0.05). Adjusted 
for the baseline measures, mean difference of 
LDL-C/HDL-C, TG/HDL-C and TC/HDL-C 
were significantly different among the groups 
(p <0.001, p =0.001 and p <0.001, respectively). 
Post-hoc analysis showed that mean difference 
of LDL-C/HDL-C was significantly higher in the 
CaD than P group (p <0.001), as well as D group 
(p = 0.006). Serum TC/HDL-C and TG/HDL-C 
level were significantly decreased in the CaD 
than P (p < 0.001 and p < 0.001), as well as D 
group (p < 0.001 and p =0.03). Mean difference 
of non-HDL-C was significantly different among 
the groups, adjusted for the baseline measures (p 
= 0.001). Serum non-HDL-C was significantly 
decreased in the CaD than P group (p < 0.001). 
Serum non-HDL-C was marginally decreased 
in the CaD compared with the D supplemented 
group (p =0.06) (Table 2).
By splitting to the sex of participants, 
significant differences were shown in ALT, TG/
HDL-C, TC/HDL-C, LDL-C/HDL-C and non-
HDL-C alterations from baseline up to the end 
of the study in females among the groups (p 
= 0.001, p = 0.007, p < 0.001, p = 0.003 and 
p = 0.005, respectively). Mean difference of 
serum ALT level was significantly higher in 
the CaD than P group (p = 0.003), as well 
as in the CaD than D supplemented group (p 
= 0.004). Mean difference of TG/HDL-C was 
significantly higher in the CaD (p = 0.01) and 
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Table1. Daily dietary intake of energy and some nutrients of the studied groups.
Dietary intake P (n = 36) D (n = 37) CaD (n = 37) p value*
Total Energy:(Kcal)
Before intervention 2157.5 ± 437.1 2160.2 ± 385.2 2162.3 ± 426.4 0.4
After intervention 1657.8 ± 391.3 1667.5 ± 345.9 1658.5 ± 364.7 0.5
Total protein(g/day)
Before intervention 75.8 ± 19.9 79.8 ± 20 76.6 ± 19.5 0.1
After intervention 60.1 ± 17.1 62.4 ± 22.7 60.5 ± 19.3 0.1
Total carbohydrate(g/day)
Before intervention 298.42 ± 72.6 296.72 ± 52.33 295.9 ± 68.5 0.31
After intervention 223.9 ± 68.52 216.3 ± 63.21 219.8 ± 62.3 0.8
Total fat(g/day)
Before intervention 73.3 ± 20 72.8 ± 24.3 73.9 ± 22.6 0.8
After intervention 57.9 ± 19.5 60.3 ± 24.7 59.7 ± 23.3 0.51
SFA1(g/day)
Before intervention 13.6 ± 6.5 13 ± 6.3 12.8 ± 5.9 0.42
After intervention 3.4 ± 6.1 3.5 ± 6.6 3.9 ± 6.5 0.52
PUFA2(g/day)
Before intervention 43.4 ± 14.7 37.7 ± 17.9 39.2 ± 16.4 0.9
After intervention 33.4 ± 19.2 32.1 ± 21.4 33.6 ± 20.8 0.4
MUFA3 (g/day)
Before intervention 6.1 ± 4.5 12.5±3.1 11.9 ± 4.2 0.54
After intervention 21.1 ± 2.3 24.7±2.7 22.2 ± 3.1 0.6
Fiber  (g/day)
Before intervention 16.7 ± 7.6 14.8 ± 5.8 15.4 ± 6.7 0.3
After intervention 13.9 ± 9.8 13.8 ± 5.5 13.5 ± 7.6 0.7
Vitamin C (mg/day)
Before intervention 127.8 ± 85.8 107.3 ± 75.9 1165 ± 81.8 0.35
After intervention 130.9 ± 83.3 110.3 ± 74.8 124.6 ± 79.9 0.34
Vitamin E (mg/day)
Before intervention 10.7 ± 8.1 13.1 ± 7.5 12.4 ± 7.9 0.25
After intervention 10.6 ± 7.9 12.7 ± 7.1 11.5 ± 6.9 0.3
calcium (mg/day)
Before intervention 777 ± 386 773 ± 586 758 ± 432 0.8
After intervention 725 ± 454 729 ± 533 792 ± 214 0.63
Vitamin D (µg/day)
Before intervention 0.39 ± 0.37 0.53 ± 0.6 0.51 ± 0.4 0.32
After intervention 0.37 ± 0.35 0.4 ± 0.47 0.39 ± 0.2 0.75
Data are expressed as means ±SD. *Differences between groups were evaluated by independent t- test
1SFA: Saturated Fatty Acid, 2PUFA: Polyunsaturated Fatty Acid, MUFA: Monounsaturated Fatty Acid
P: placebo group; D: vitamin D supplemented group as calciferol; CaD: calcium plus vitamin D supplemented group.
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Table 2. Anthropometric and biochemical measures at baseline and week 12 and changes from baseline up to the end of the study1.
Variables P (n = 36) D (n = 37) CaD (n = 37) p value
BMI, kg/m2
- Baseline 31.3 ± 0.58 30.3 ± 0.64 30.5 ± 0.93 0.69†
- Week 12 29.9 ± 0.46 29.2 ± 0.67 29.2 ± 0.87 0.65
- Treatment effect -1.4 ± 0.29 -1.1 ± 0.13 -1.3 ± 1.2 0.78‡
WHR
- Baseline 0.98 ± 0.01 0.97 ± 0.01 0.99 ± 0.01 0.8
- Week 12 0.97 ± 0.01 0.96 ± 0.01 1.02 ± 0.006 <0.001
- Treatment effect -0.01 ± 0.01 -0.017 ± 0.01 0.03 ± 0.01 0.001
BF, %
- Baseline 34.9 ± 1.3 35.3 ± 1.2 38.4 ± 0.98 0.07
- Week 12 32.6 ± 1.3 33 ± 1.2 34.7 ± 0.98 0.1
- Treatment effect -2.36 ± 0.49 -2.25 ± 0.36 -3.67 ± 0.46 0.05
ALT, µmol/L
- Baseline 46.5 ± 3.01 45.9 ± 2.4 50.2 ± 2.6 0.44
- Week 12 47.3 ± 2.6 42.4 ± 2.6 35.8 ± 1.4 <0.001
- Treatment effect a, b 0.5 ± 2.1 -3.5 ± 1.8 -14.4 ± 1.7 <0.001
AST, µmol/L
- Baseline 31.1 ± 1.6 30.4 ± 1.3 32.5 ± 1.2 0.48
- Week 12 28.6 ± 1.8 26.3 ± 1.5 26.9 ± 1.2 0.04
- Treatment effect a -2.5 ± 1.02 -4.2 ± 0.71 -5.52 ± 0.61 0.028
LDL-C/HDL-C
-Baseline 3.1 ± 0.16 3.1 ± 0.15 3.56 ± 0.15 0.08
-Week 12 3.2 ± 0.14 3 ± 0.13 3 ± 0.11 0.5
-Treatment effect a, b 0.07 ± 0.07 -0.14 ± 0.09 -0.56 ± 0.11 <0.001
TG/HDL-C
- Baseline 5.7 ± 0.54 5.7 ± 0.45 6.2 ± 0.34 0.7
- Week 12 5.5 ± 0.44 4.6 ± 0.33 4.5 ± 0.25 0.5
- Treatment effect a, c -0.22 ± 0.25 -1.1 ± 0.29 -1.7 ± 0.21 0.001
TC/HDL-C
- Baseline 5.2 ± 0.24 5.3 ± 0.24 5.8 ± 0.22 0.16
- Week 12 5.3 ± 0.22 5.03 ± 0.17 4.7 ± 0.12 0.07
- Treatment effect a, b 0.15 ± 0.12 -0.26 ± 0.14 -1.04 ± 0.14 <0.001
Non-HDL-C
- Baseline 148.5 ± 5.8 151.1 ± 5.5 163.3 ± 6 0.16
- Week 12 154.9 ± 5.1 150.7 ± 5.5 154.2 ± 5.2 0.83
- Treatment effect a 6.4 ± 3.3 -0.4 ± 2.6 -9.1 ± 2.5 0.001
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D (p = 0.03) than P group. TC/HDL-C and non-
HDL-C were significantly decreased in the CaD 
(p < 0.001 and p = 0.008) and D (p = 0.004 and 
p = 0.03) than P group. Alterations in serum 
TC/HDL-C was significantly higher in the CaD 
than D supplemented group (p =0.003), after 12 
weeks of treatment. Mean difference of LDL-C/
HDL-C was significantly higher in the CaD (p 
= 0.007) and D (p = 0.01) than P group. Serum 
LDL-C/HDL-C was significantly decreased in 
the CaD compared with D supplemented group 
(p < 0.001) after 12 weeks of treatment. 
In males, significant differences were shown 
in mean difference of serum ALT, TG/HDL-C, 
TC/HDL-C, LDL/HDL-C and non-HDL-C at 
the end of the treatment (p =0.001, p = 0.04, p 
<0.001, p < 0.001 and p = 0.02, respectively). 
ALT alteration was significantly higher in the 
CaD than P group (p = 0.001), as well as 
the D group (p = 0.01). After 12 weeks of 
supplementation, TG/HDL-C, TC/HDL-C and 
LDL-C/HDL-C were significantly decreased 
in the CaD compared with the P group (p = 
0.03, p = 0.01 and p = 0.03, respectively). 
Mean difference of TG/HDL-C, TC/HDL-C 
and LDL-C/HDL-C were significantly higher 
in the CaD than P group (p = 0.04, p =0.002 
and p =0.007, respectively). Furthermore, mean 
difference of TC/HDL-C, LDL-C/HDL-C and 
non-HDL-C were significantly higher in the CaD 
than D supplemented group (p =0.002, p =0.001 
and p = 0.02, respectively). 
With considering the BMI changes as 
covariate, reduction in the grade of fatty liver 
was significant in the CaD and D supplemented 
groups relative to the P (p < 0.001). In the P 
group, no change was seen in the grade of fatty 
liver in 89% of participants (N = 32) at the end of 
the study. In the D supplemented group, 89% of 
participants (N = 33) had 1 degree reduction in 
the grade of fatty liver. In the CaD supplemented 
group, 62% (N = 23) and 10.8% (N = 4) of 
participants had 1 degree and 2 degree reduction 
in fatty liver grade, respectively. 
Discussion
To the best of our knowledge, this is the first 
randomized, placebo-controlled, double-blind 
clinical trial to evaluate the beneficial effects of 
oral calcium plus vitamin D supplementation, 
compared to vitamin D alone, on atherogenic 
indices in NAFLD patients. Despite the well-
documented role of calcium in cell metabolism, 
its role in the development of cardiovascular 
disease is still inconclusive (20-23). Several 
studies suggest that calcium supplementation 
might be associated with an increased risk of 
coronary heart disease (20, 23), whereas others 
underline a significant effect on lowering high 
blood pressure and hyperlipidemia (22-26). Our 
results suggest that CaD supplementation has 
Variables P (n = 36) D (n = 37) CaD (n = 37) p value
25 (OH) Da, ng/ml
- Baseline 10 ± 0.63 9.9 ± 0.64 9.9 ± 0.64 0.9
- Week 12 11 ± 0.78 21.4 ± 0.73 27.1 ± 1.1 <0.001
- Treatment effect a, b, c 0.98 ± 0.35 11.5 ± 0.96 17.3 ± 0.99 <0.001
1Values are means ± SE. p<0.05 was considered as significant. a To convert 25(OH) D values to ng/mL, divide by 2.5.
WHR, waist to hip ratio; BF, body fat; TC, total cholesterol; TG, triglyceride; ALT, alanine amino-transferase; AST, aspartate amino-
transferase.
P: placebo group; D: vitamin D supplemented group as calciferol; CaD: calcium plus vitamin D supplemented group.
†p values are related to the differences among the groups; evaluated by one-way ANOVA.
‡P values are for the supplemented groups relative to the placebo group by using an ANCOVA with baseline values as covariate.
a Significant difference between the CaD and placebo group; b Significant difference between the CaD and D group; c Significant difference 
between the D and placebo group (p<0.05).
Table 2. Continued.
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more beneficial effects on atherogenic factors 
including LDL-C/HDL-C, TC/HDL-C, TG/
HDL-C and non-HDL-C in NAFLD patients. 
Reduction in serum ALT level was significantly 
higher in the CaD supplemented group than 
others. Non-HDL-C was significantly decreased 
in the CaD than P group. This effect was marginal 
in the CaD compared with the D group. 
Previous studies have shown that ratios of 
cholesterol ester-rich lipoprotein levels (TC/
HDL-C and LDL-C/HDL-C), as well as TG/
HDL-C are strong predictors of insulin resistance 
and LDL particle diameter (small-dense LDL-
C), and ultimately CVD (27-29). Our results are 
in agreement with the previous studies which 
showed an inverse association between serum 
levels of TG and HDL-C in adults with pre-
diabetes (30), as well as lipid profile, insulin 
sensitivity and liver enzyme tests with vitamin 
D in NAFLD patients (31). Moreover, some 
studies showed a negative correlation between 
serum 25 (OH) D levels and TG, as well as low 
HDL-C levels (32-34). In contrast, one cross-
sectional study on healthy participants with a 
mean BMI of 23.8 kg/m2 showed no significant 
correlation between serum lipid profile and 
vitamin D levels (35). It may be suggested that 
serum levels of vitamin D are related with lipid 
profile and atherogenic indices in patients with 
inflammatory conditions. Several mechanisms 
are suggested for these effects. Low serum levels 
of 25 (OH) D leads to hyperparathyroidism 
which decrease peripheral removal of TG and 
activate microsomal TG-transfer protein and 
induce hypertriglyceridemia (35, 36). Also, 
it is suggested that vitamin D may regulate 
macrophage function on reverse cholesterol 
transport and improve free fatty acids-induced 
insulin resistance and inflammation (37, 38). 
Effects of calcium supplementation were 
measured on lipid profile and atherogenic index 
of plasma (AIP) in centrally obese men (16). 
Oral 1500 mg/day calcium supplementation for 
8 weeks resulted in 22% reduction in TG and 
19.2% in HDL-C levels. Significant reduction in 
serum TC and LDL-C levels were only found in 
dyslipidemic and centrally obese subjects. AIP 
decreased significantly by 51% with calcium 
carbonate treatment. 
Non‐HDL‐C is an excellent diagnostic 
marker for lipid disorders and CVD risk (39, 
40). It presents full impact of all plasma lipid 
components involved in atherogenesis including 
chylomicrones, VLDL and their remnants, 
IDL, LDL and Lp (a), except HDL (41). The 
concentration of non‐HDL‐C is calculated using 
total cholesterol minus HDL-C. A meta‐analysis of 
lipid‐lowering therapies showed a 1:1 correlation 
between the lowering of non‐HDL‐C and CVD 
risk (42). One study found that 1 mg/dL increase 
in non‐HDL‐C, increases the risk of CVD death 
by 5% (39). In a cross-sectional study, each 10 
nmol/L increase in 25(OH) D was associated 
with a decrease in non-HDL-C concentration 
(-0.89 mg/dl) (43). Our results are in agreement 
with the mentioned study. Alteration in serum 
non-HDL-C was significantly higher in the D 
supplemented than the P group. On the other 
hand, CaD supplementation had more effects on 
serum non-HDL-C reduction than D, alone. But 
this effect was marginally significant due to small 
sample size. There are conflicting results with a 
non-selected cohort study in south Italy in which 
a significant association was shown between TC, 
LDL-C, HDL-C, non-HDL-C, TG and serum 
calcium in men and postmenopause women (44). 
It seems that the relationship between calcium 
and/or vitamin D supplementation and CVD is 
influenced by the type of intervention, duration, 
supplement dosage, and participants (45). To 
our knowledge this is the first study about the 
effects of vitamin D alone and/or in combination 
with calcium on atherogenic indices in NAFLD 
patients and showed that CaD supplementation 
had positively effect on lipid profile and 
atherogenic indices compared with the D and 
P groups. Also, a larger sample size and longer 
duration are needed before reaching conclusive 
results. There are some limitations to our results; 
most importantly that NAFLD was diagnosed by 
biochemical and ultra sonographic findings in 
our patients, which is not possible to distinguish 
between simple fatty liver and NASH. Liver 
biopsy is the gold standard to NAFLD diagnosis, 
but it is an invasive and expensive method. We 
should note that the levels of ALT and AST were 
quasi in normal range. Therefore, the grade of 
fatty accumulation was not great in the majority 
of the patients. Another study with the higher 
levels of these enzymes is needed to assess the 
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effects of Calciferol with and/or without calcium 
on NAFLD progression.  
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